Immune checkpoint inhibitors in cancer treatment and potential effect modification by age

Acta Oncol. 2020 Mar;59(3):247-248. doi: 10.1080/0284186X.2020.1724329. Epub 2020 Feb 8.

Authors

Hanna Eriksson^{1

2}, Karin E Smedby^{2

3}

Affiliations

¹ Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
² Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
³ Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

PMID: 32036733
DOI: 10.1080/0284186X.2020.1724329

No abstract available

Publication types

Editorial

MeSH terms

Age Factors
Antineoplastic Agents, Immunological / therapeutic use*
B7-H1 Antigen / antagonists & inhibitors*
CTLA-4 Antigen / antagonists & inhibitors*
Humans
Immunotherapy / methods*
Neoplasms / drug therapy*
Neoplasms / immunology
Neoplasms / pathology

Substances

Antineoplastic Agents, Immunological
B7-H1 Antigen
CD274 protein, human
CTLA-4 Antigen
CTLA4 protein, human